|
|
|
|
Tuesday, May 26, 2020
Genprex Inc.(GNPX)
Emerging as a Leader in Cancer Gene Therapy
Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.
Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Unique Gene Therapy Technology. We believe that Genprex will emerge as a leader in the area of gene therapy for the treatment of cancer. Genprex is developing a unique platform technology consisting of the use of lipid nanoparticles designed to restore normal tumor suppressor protein levels in cancer cells to induce apoptosis (programmed cell death), inhibit tumor progression and prolong survival of cancer patients.
GEN-001 for the Treatment of Lung Cancer. Genprex’s lead product, GEN-001, in combination with AstraZeneca’s Tagrisso or Merck’s Keytruda, will be evaluated in Phase I/II clinical trials for the treatment of non-small cell lung cancer (NSCLC). Previous clinical results showed a disease control rate (DCR) of….
Click to get the full report.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.